Body Handbook კატალოგი პროფილი რეიტინგი
ჯანდაცვა BODY HANDBOOK
ჯანდაცვა · §669
ბიოლოგიური პრეპარატები ტიპი 2 ანთებისთვის
Severe eczema, uncontrolled asthma, nasal polyps that killed your sense of smell, and food that gets stuck going down look like four diseases. Here's what you didn't know you didn't know: they're often one disease, an immune program called Type 2 inflammation running through different organs. A class of injected drugs shuts that program off, and one of them, dupilumab, is approved across seven conditions. In the right patient the itch stops in days and the flares roughly halve over a year.
გადაწყვიტე · ყოველდღე მტკიცებულება ძლიერი თავი ჯანდაცვა

One cascade, many organs. Allergy, eczema, asthma, polyps, and eosinophilic esophagitis all run on the same signaling proteins: IL-4, IL-5, and IL-13. Dupilumab blocks the docking port IL-4 and IL-13 both use, silencing two signals at once 1. The IL-5 drugs (mepolizumab, benralizumab) instead wipe out the eosinophil, the cell that drives much of the airway and gut damage.

Fast and large, in the right phenotype. Severe eczema: about half hit a 75% skin-score drop by week 16, against roughly 15% on placebo, itch falling in the first week 2. Severe asthma: attack rate cut by about half over a year 3. Nasal polyps: smell restored within weeks, repeat sinus surgery cut by roughly 80% 4. Eosinophilic esophagitis, with no approved drug until 2022: tissue remission in about 60% versus 5% on placebo 5. In the wrong phenotype it does nothing.

The gate comes before the needle. The drug only works on disease actually driven by these signals, so the phenotype has to be confirmed first.

The arc, if you're a responder.

  • Week 1: the itch drops in eczema and prurigo; you sleep through the night.
  • Week 2: asthma breathing function climbs; the rescue inhaler starts gathering dust.
  • Month 1: eczema patches fade, polyp patients smell coffee again.
  • Month 3: food stops sticking in EoE; you eat without picking the menu by softness.
  • Year 1: asthma attacks roughly halved, and the steroid bursts that were quietly costing you bone and mood stop 2 3.

The real burden is money, not side effects. US list price runs about $3,000 a month, or $35,000–$40,000 a year 6. Most insured patients never pay it: plans cover it after prior authorization, and copay cards cap the cost near $0–$100 a month. The prior-authorization fight itself takes months and is the routine obstacle.

The fine print — when to skip it, and what people get wrong

Don't start with an active parasite (helminth) infection; blocking the Type 2 response is what clears them. Pregnancy data is limited and the antibodies cross the placenta. Avoid live vaccines during therapy.

"Biologics suppress your immune system" is wrong here: these dial down only the allergy arm, and infection risk stays near placebo-level 6. And it doesn't work for everyone with asthma; about 20% is a non-Type-2 pattern that won't respond.

The signature side effect of dupilumab is conjunctivitis, pink irritated eyes, in about 17% of eczema patients and the top reason people quit 7. It barely appears in asthma or polyp patients, and most cases clear with drops.

References
  1. 1Le Floc'h A, Allinne J, Nagashima K, et al. (2020). Dual blockade of IL-4 and IL-13 with dupilumab, an IL-4Rα antibody, is required to broadly inhibit type 2 inflammation. Allergy. link
  2. 2Simpson EL, Bieber T, Guttman-Yassky E, et al. (2016). Two Phase 3 Trials of Dupilumab versus Placebo in Atopic Dermatitis (SOLO 1 and SOLO 2). New England Journal of Medicine. link
  3. 3Castro M, Corren J, Pavord ID, et al. (2018). Dupilumab Efficacy and Safety in Moderate-to-Severe Uncontrolled Asthma (LIBERTY ASTHMA QUEST). New England Journal of Medicine. link
  4. 4Bachert C, Han JK, Desrosiers M, et al. (2019). Efficacy and safety of dupilumab in patients with severe chronic rhinosinusitis with nasal polyps (LIBERTY NP SINUS-24 and LIBERTY NP SINUS-52). The Lancet. link
  5. 5Dellon ES, Rothenberg ME, Collins MH, et al. (2022). Dupilumab in Adults and Adolescents with Eosinophilic Esophagitis (LIBERTY EoE TREET). New England Journal of Medicine. link
  6. 6McCann MR, Kosloski MP, Xu C, et al. (2024). Dupilumab: Mechanism of action, clinical, and translational science. Clinical and Translational Science. link
  7. 7Akinlade B, Guttman-Yassky E, de Bruin-Weller M, et al. (2019). Conjunctivitis in dupilumab clinical trials. British Journal of Dermatology. link
დაკავშირებული სახელმძღვანელოში (10)
ეხმარება
  • — Dupilumab is now an approved fix for EoE — the same IL-4/13 block that clears eczema ends the food-sticking.
  • — Nasal polyps are one of the conditions these biologics treat — an option when steroids and rinses aren't enough.
Works well with
  • — Severe allergic asthma is a core use — these biologics roughly halve attacks when inhalers aren't enough.
ალტერნატივები
  • — Don't want a weekly injection for EoE or eczema? A dietitian-run elimination diet treats the same allergic inflammation from the food side.
  • — Don't escalate to a biologic on a missed inhaler: fixing technique often recovers control without changing the drug.
დაკავშირებული
  • — Stubborn allergic nasal disease with polyps is part of the Type 2 inflammation family these biologics treat.
  • — For the eosinophilic subtype of COPD, a Type 2 biologic is a newer add-on beyond the standard inhaler plan.
  • — Hidradenitis is one of the inflammatory diseases these biologics now treat.
  • — IBD is another inflammatory disease where leading with a biologic early changes the long-term course.
  • — When moisturizer and steroid creams can't control eczema, a Type 2 biologic is the next step up.
·
669